Home > Insider Trading > Filing (0001209191-16-090065)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1435049	Aduro Biotech Inc.	ADRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1465994	Jennifer Lew	C/O Aduro Biotech, Inc. 626 Bancroft Way, 3C Berkeley CA 94710	Sr. Vice President Of Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-01-06	5,242	$0.82	11,442	No	4	M	Direct
Common Stock	Disposition	2016-01-06	4,442	$25.64	7,000	No	4	S	Direct
Common Stock	Disposition	2016-01-06	800	$26.09	6,200	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2016-01-06	5,242	$0.00	5,242	$0.82

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
124,074		2023-11-26	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.02 to $25.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.05 to $26.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Twenty-five percent of the shares subject to the Option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.